Walgreens Boots Alliance (WBA) stock is soaring Friday, up more than 20% to make it the best S&P 500 stock at last check, after the drugstore chain beat top- and bottom-line expectations for its fiscal 2025 first quarter and maintained its full-year profit forecast.
In the three months ended November 30, Walgreens' revenue increased 7.5% year over year to $39.5 billion, driven by growth across all business segments. Its earnings per share (EPS) declined 22.7% from the year-ago period to 51 cents.
"Our first-quarter results reflect our disciplined execution against our 2025 priorities: stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow and continuing to address reimbursement models," said Walgreens CEO Tim Wentworth in a statement. "While our turnaround will take time, our early progress reinforces our belief in a sustainable, retail pharmacy-led operating model."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The results handily beat analysts' expectations. Wall Street was anticipating revenue of $37.4 billion and earnings of 37 cents per share, according to CNBC.
Walgreens also maintained its full-year profit forecast, which calls for earnings per share in the range of $1.40 to $1.80.
Is Walgreens stock a buy, sell or hold?
Walgreens' troubles on the price charts have been well-documented. Indeed, heading into Friday's session, sharewere down more than 61% on a year-over-year basis. Unsurprisingly, Wall Street is on the sidelines when it comes to the consumer staples stock.
According to S&P Global Market Intelligence, the average analyst target price for WBA stock is $10.43, representing a discount of nearly 10% to current levels. Meanwhile, the consensus recommendation is Hold.
Financial services firm UBS Global Research is one of those with a Neutral (Hold) rating on the mid-cap stock, along with a $10 price target.
"We believe WBA's fundamentals remain challenged exiting [its] fiscal first quarter," wrote UBS Global Research analyst Kevin Caliendo in a January 5 note. "Pharmacy chain script growth has remained soft, flu season started later than last year, creating a difficult comparison for fiscal Q1, and retailer peers are calling out deal-seeking behavior by consumers and mixed commentary around holiday season sales expectations. However, this reflects more or less a continuation of the status quo over the past nine-plus months."
Related Content
- Earnings Calendar and Analysis for This Week
- Delta Stock Remains a Strong Buy After Earnings
- Amazon to Replace Walgreens in the Dow: Why This Matters
-
Stock Market Today: Good Feelings and Solid Data Lift StocksResilience and de-escalation defined another generally positive day for financial markets.
-
Five Home Upgrades for Surviving Record-Breaking HeatWith global temperatures expected to hover at record highs for years to come, now’s the time to upgrade your home for long-term heat resilience.
-
Stock Market Today: Good Feelings and Solid Data Lift Stocks
Resilience and de-escalation defined another generally positive day for financial markets.
-
What the HECM? Combine It With a QLAC and See What HappensCombining a reverse mortgage known as a HECM with a QLAC (qualifying longevity annuity contract) can provide longevity protection, tax savings and liquidity for unplanned expenses.
-
721 UPREIT DSTs: Real Estate Investing Expert Explores the Hidden RisksPotential investors need to understand the crucial distinction between a REIT's option to buy a Delaware statutory trust's property and its obligation.
-
I'm an Insurance Expert: Yes, You Need Life Insurance Even if the Kids Are Grown and the House Is Paid OffLife insurance isn't about you. It's about providing for loved ones and covering expenses after you're gone. Here are five key reasons to have it.
-
Stock Market Today: Tesla Drags on Stocks Amid Musk-Trump FeudSentiment has soured between President Trump and his once-loyal ally, Tesla CEO Elon Musk.
-
My Professional Advice: When It Comes to Money, You Do YouThis is how embracing the 'letting others be' and 'learning to surrender' mindsets can improve your relationship with money.
-
Direct Indexing Expert Explains How It Can Be a Smarter Way to InvestDirect indexing provides a more efficient approach to investing that can boost after-tax returns, but is it right for you?
-
Stock Market Today: Stocks Brush Off Weak Jobs DataThe yields on the 2-year and 10-year Treasury notes fell sharply after a pair of weak economic reports.
